Prof. Robert R. Conley

powered by
COS Expertise®
University of Maryland at Baltimore
Medicine
Psychiatry
Maryland Psychiatric Research Center
ProfessorAppointed: 2003
University of Maryland at Baltimore
Pharmacy
Pharmacy Practice and Science
ProfessorAppointed: 2003
Professional Headshot of Robert R. Conley

Mailing Address

P.O. Box 21247
Maryland Psychiatric Research Center
Baltimore, Maryland 21201
United States

Contact Information

Phone: (410) 402-6860
Fax: (410) 402-6880
rconley@umaryland.edu

Qualifications

Chief Resident, University of Pittsburgh, Psychiatry, 1986.
Residency, University of Pittsburgh, Psychiatry, 1985.
M.D., University of Maryland at Baltimore, 1981.
B.A., Johns Hopkins University, Natural Science, History of Science, 1977.

Expertise and Research Interests

My work is focused on comparing the clinical effects of medications in people with schizophrenia, including those who are refractory to therapy, have metabolic abnormalities or have a substance abuse diagnosis. Our group performs large clinical trials, outcome studies, and human post-mortem studies. Our group provides the clinical characterization of the subjects in the Maryland Brain Collection. I actively work in the area of research ethics, particularly in the area of evaluation of ability to consent.

My past work has included evaluations of remoxipride and olanzapine, multiple studies with clozapine, and, most recently completed, a double blind evaluation of quetiapine, risperidone, or fluphenazine. We have also begun to do extensive work in adjunct pharmacotherapy for schizophrenia. Our group now is conducting five trials employing adjunct pharmacotherapy in partially responsive people with schizophrenia: glycine or cycloserine for negative symptoms, risperidone in partial clozapine responders, preclamol in partial clozapine responders, galantamine in people with schizophrenia and persistent cognitive deficits and atomoxetine in people with schizophrenia and persistent cognitive deficits.

Our work the direct evaluation of human brain tissue includes biochemical patterns relating to the likelihood of suicide and cell migration and synaptic changes associated with severe mental illness.

Other Expertise

Chairman of the Institutional Review Board for the National Institute of Drug Abuse
Executive Committee for University of Maryland, Baltimore Institutional Review Board
Director of Research, Perry Point Veterans Affairs Medical Center, Perryville, Maryland
Member, Human Research Policy Advisory Committee, University of Maryland, Baltimore

Future Research

Synaptic changes associated with anitpsychotic therapy
Cell migration abnormalities in schizophrenia and related psychoses
Genetics of psychosis
Neuropharmacology of dysphoria
Treatment of dually diagnosed people with psychosis
Real world outcome of psychoactive drug therapy
Treatment of the Dually-Diagnosed

Industrial Relevance

Clinical trials research
Bioethics of human studies

Keywords

COS Keywords:

Agent Or Drug Screening, Chemotherapy, Clinical Trial, Dopamine, Drug Resistance, Forensic Science, History of Medicine, Human Subjects Policy, Medical Diagnosis, Mental Disorders, Mental Health, Mental Health Services, Neuropsychopharmacology, Pharmacy, Psychiatry, Psychopharmacology, Schizophrenia, Synaptic Transmission.

Additional Terms:

Antipsychotic Agent, Benztropine, Chlorpromazine, Clinical Trial, Clozapine, Dopamine Antagonist, Dosage, Drug Administration Rate Duration, Drug Adverse Effect, Drug Resistance, Drug Screening Evaluation, Extrapyramidal Disorder, Haloperidol, Human Subject, Human Therapy Evaluation, Mental Disorder Chemotherapy, Mental Disorder Diagnosis, Psychopharmacology, Quetiapine, Risperidone, Schizophrenia.

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)
French: (Functional, Basic, Basic)
German: (Basic, Basic, None)

Memberships

Alpha Omega Alpha
American Association for the Advancement of Science
American Association for the History of Medicine
American College of Neuropsychopharmacology
Society for Neuroscience
Society of Biological Psychiatry

Honors and Awards

2002, Exemplary Psychiatrist, National Alliance for the Mentally Ill
1999-2003, Chairman, APA Resident Scholars Travel Award Committee, Jannsen Pharmaceutica, American Psychiatric Association
1998, Educator of the Year, Florida Alliance for the Mentally Ill
1996, Walter Weintraub Teacher of the Year, Department of Psychiatry, University of Maryland at Baltimore
1988, Exemplary Psychiatrist, Pennsylvania Alliance for the Mentally Ill
1987, Young Investigator Award, The International Congress on Schizophrenia Research
1984, Laughlin Award for Merit, National Psychiatric Endowment Fund Fellowship
1981, William Alexander Hammond Award, University of Maryland at Baltimore, Neurology

Previous Positions

1998-2003, Associate Professor, University of Maryland at Baltimore, Pharmacy
1998-2003, Associate Professor, University of Maryland at Baltimore, Medicine, Psychiatry, MPRC
1996-1998, Assistant Professor, University of Maryland at Baltimore, Medicine, Psychiatry, MPRC
1989-1996, Research Assistant Professor, University of Maryland at Baltimore, Medicine, Psychiatry, MPRC
1988-1989, Adjunct Assistant Professor, University of Pittsburgh, School of Medicine, Psychiatry, Western Psychiatric Institute and Clinic
1987-1988, Instructor, University of Pittsburgh, School of Medicine, Psychiatry, Western Psychiatric Institute and Clinic
1981-1986, Resident/Chief Resident, University of Pittsburgh, School of Medicine, Psychiatry, Western Psychiatric Institute and Clinic
1977-1981, Medical Student, University of Maryland at Baltimore, Medicine
1973-1977, Student, Johns Hopkins University, Krieger School of Arts and Sciences

Funding Received

  • National Institute on Drug Abuse: Residential Research Support Services for Research in Dual Diagnosis, , 2005 to 2010.
  • Stanley Research Foundation: Atomoxetine as an adjunct in the treatment of schizophrenia, , 2002 to 2006.
  • National Institutes of Health (NIH): Risperidone in Partial Clozapine Responders, , 2002 to 2008.
  • Stanley Research Foundation: Galantamine Treatment of Schizophrenia, , 2001 to 2004.
  • Stanley Research Foundation: 3PPP in treatment resistant patients with schizophrenia, , 2001 to 2003.
  • Stanley Research Foundation: Sexual function and prolactin levels with atypical antipsychotics, , 1999 to 2001.
  • National Institutes of Health (NIH): Research Ethics in Schizophrenia, , 1999 to 2004.
  • Stanley Foundation: Determining the Effectiveness/Novel Antipsychotic Agents, , 1998 to 2000.
  • Stanley Research Foundation: Determining the effectiveness of novel antipsychotic agents, , 1998 to 2000.
  • Jassen Research Foundation: Multicenter, placebo-controlled, double-blind comparison of risperidone and olanzapine in schizophrenia, , 1997 to 1998.
  • Abbott Laboratories Fund: Clinical Study M95-372 of Sertindole and Risperidone, , 1996 to 1998.
  • Abbott Laboratories Fund: Assessment of the Long-Term Safety of Sertindole, , 1996 to 1999.
  • Merck Sharp and Dohme: Antipsychotic Activity/L-745,870/Hospitalized Schizophrenia, , 1995 to 1995.
  • R.W. Johnson Pharm Res Inst: Behavioral Activity of RWJ-33796 in Male Schizophrenics, , 1993 to 1996.
  • National Institutes of Health (NIH): Serotonin Receptors in Teenage Suicide and their Families, , 1992 to 1996.
  • National Institutes of Health (NIH): New Antipsychotic Neuroleptic Strategies/Schizophrenia, , 1992 to 2004.
  • Merck Sharp and Dohme: Open label Remoxipride/treatment of Schizophrenic Patients, , 1991 to 1993.
  • Scottish Rite Research Program: Evaluation of Clozapine effects on Dopamine/Serotonin, , 1990 to 1992.
  • Scottish Rite Research Program: Psychoactive substance use assessment in Schizophrenia, , 1990 to 1992.
  • Merck Sharp and Dohme: Remoxipride vs Haloperidol in Schizophrenia, , 1990 to 1991.
  • NARSAD: Eval of Clozapine effect on Dopamine/Serotonin receptors, , 1990 to 1992.
  • National Institutes of Health (NIH): Advanced Center for intervention and Clinical Research: Classification and Course of the Schizophrenia (core PI), , 1988 to 2008.

Publications

  • Dwivedi Y, Mondal AC, Rizavi HS, Conley RR (Aug 2005) Suicide brain is associated with decreased expression of neurotrophins, Biological Psychiatry, 58 (4), 315-24
  • Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Mondal AC, Shukla PK, Conley RR (Aug 2005) Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims, Neuropsychopharmacology, 30 (8), 1548-56
  • Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker SP, Roberts RC, Bunney WE Jr, Conley RC, Jones EG, Tamminga CA, Guo Y (Aug 2005) Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia, 62 (8), 829-40
  • Roberts RC, Roche JK, Conley RR (Jun 2005) Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis, 56 (4), 185-97
  • Shim JC, Kim YH, Kelly DL, Lee JG, Conley RR (Spring 2005) Tardive dyskinesia predicts prolactin response to buspirone challenge in, The Journal of Neuropsychiatry and Clinical Neurosciences, 17 (2), 221-6
  • Conley RR, Kelly DL, Lambert TJ, Love RC (Mar 2005) Comparison of clozapine use in Maryland and in Victoria, Australia, 56 (3), 320-3
  • Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love RC (Jul-Aug 2005) Risperidone, quetiapine, and fluphenazine in the treatment of patients, Clin Neuropharmacol, 28 (4), 163-8 Abstract
  • Kelly DL, Conley RR (Jan 2005) Thyroid function in treatment-resistant schizophrenia patients treated, The Journal of Clincal Psychitary, 66 (1), 80-4
  • Kelly DL, Conley RR, Carpenter WT (2005) First-episode schizophrenia: a focus on pharmacological treatment and, Drugs, 65 (8), 1113-38
  • McMahon RP, Arndt S, Conley RR (Jan 2005) More powerful two-sample tests for differences in repeated measures of, Statistics in Medicine,, 24 (1), 11-21
  • Conley RR, Kelly DL (2005) Second-generation antipsychotics for schizophrenia: a review of clinical, The Israel Journal of Psychiatry and Related Sciences, 42 (1), 51-60
  • Conley RR, Kelly DL (2005) Schizophrenia In Rakel R, Bope E (eds), Conn's Current Therapy 2005, Philadelphia, PA, W.B. Saunders Co. (bookchapter)
  • Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ, The heterogeneity of schizophrenia in disease states, Schizophrenia Research, 71(1), 83-95, November 2004
  • Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B, Practical application of pharmacotherapy with long-acting risperidone for, Psychiatric Services, 55(9), 997-1005, Sep 2004
  • Kelly DL, Shim JC, Feldman SM, Yu Y, Conley RR (Sep-O 2004) Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death, Journal of Psychiatric Research, 38 (5), 531-6
  • Conley RR, Kelly DL, Beason-Held LL, Holcomb HH, Richardson CM (Sep 2004) The effects of clozapine and high-dose olanzapine on brain function in, Journal of Psychopharmacology, 18 (3), 429-31
  • Love RC, Conley RJ (Sep 2004) Long-acting risperidone injection, Am J Health Syst Pharm, 61 (17), 1792-800
  • Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Conley RR, Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study, Archives of General Psychiatry, 61(7), 685-93, July 2004
  • Kim YH, Shim JC, Kelly DL, Lee JG, Seo YS, Conley RR, Cortisol response to buspirone in extended abstinent alcoholics, Alcohol and Alcoholism, 39(4), 287-9, 2004
  • Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update, Journal of Clinical Psychiatry, 65 (4), 500-8
  • Kelly DL, Love RC, MacKowick M, McMahon RP, Conley RR (2004) Atypical antipsychotic use in a state hospital inpatient adolescent population, Journal of Child and Adolescent Psychopharmacology, 14 (1), 75-85
  • Dwivedi Y, Rizavi HS, Shukla PK, Lyons J, Faludi G, Palkovits M, Sarosi A, Conley RR, Roberts RC, Tamminga CA, Pandey GN, Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits, Biological Psychiatry, 55(3), 234-43, February 2004
  • Lambert T, Kelly DL, Alcock S, Conley RR (2004) Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis, Journal of Clinical Psychopharmacology, 24 (1), 91-3
  • Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA (January 2004) Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics, Journal of Clinical Psychiatry, 65 (1), 120-31
  • Kelly DL, Conley RR, Sexuality and Schizophrenia: a Review, Schizophrenia Bulletin, 30(4), 767-79, 2004
  • Wehring HJ, Kelly DL, Love RC, Conley RR (2003) Deaths from diabetic ketoacidosis after long-term clozapine treatment, The American Journal of Psychiatry, 160 (12), 2241-2
  • Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr (Dec 2003) The Efficacy of High-dose Olanzapine Versus Clozapine In Treatment-resistant Schizophrenia: a Double-blind Crossover Study., Journal of Clinical Psychopharmacology, 23 (6), 668-71
  • Nelson MW, Reynolds RR, Kelly DL, Conley RR, Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone, Clinical Neuropharmacology, 26(6), 297-8, 2003
  • Shim JC, Kelly DL, Kim YH, Yoon YR, Park JH, Shin JG, Conley RR (October 2003) Fluoxetine augmentation of haloperidol in chronic schizophrenia, Journal of Clinical Psychopharmacology, 23 (5), 520-2
  • Kelly DL, Conley RR, Evaluating sexual function in patients with treatment-resistant schizophrenia, Schizophrenia Research, 63(1-2), 195-6, September 2003
  • Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, Conley RR, Tamminga C (2003) Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression, Journal of Psychiatric Research, 37 (5), 421-32
  • Kirkpatrick B, Messias NC, Conley RR, Roberts RC (September 2003) Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia, Journal of Nervous and Mental Disease, 191 (9), 563-7
  • Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR (September 2003) Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine, Journal of Clinical Psychiatry, 64 (9), 1133-4
  • Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN, Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects, Archives of General Psychiatry, 60(8), 804-15, August 2003
  • Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR, Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement, Human Psychopharmacology, 18(5), 405-11, July 2003
  • Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, Tamminga CA, Pandey GN, Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects, Archives of General Psychiatry, 60(3), 273-82, March 2003
  • Kelly DL, Gale EA, Conley RR (March 2003) Clozapine treatment in patients with prior substance abuse, Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 48 (2), 111-4
  • Conley RR, Kelly DL, Love RC, McMahon RP (Mar 2003) Rehospitalization Risk With Second-generation and Depot Antipsychotics, Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists, 15 (1), 23-31
  • Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS (2003) Clinical guidelines: Dosing and switching strategies for long-acting risperidone, Journal of Clinical Psychiatry, 64 Suppl 16, 41-6
  • Conley RR, Kelly DL (2003) Pharmacologic Treatment of Schizophrenia, Second Edition, Professional Communications, Inc.
  • Conley RR, Kelly DL (2003) The long-term efficacy, effectiveness and safety of second-generation antipsychotics In Csernansky JG, Lauriello J (eds), Atypical antipsychotics: a bench to bedside perspective for clinicians (bookchapter)
  • Nelson MW, Reynolds RR, Kelly DL, Conley RR, Adjunctive Quetiapine Decreases Symptoms of Tardive Dyskinesia in A Patient Taking Risperidone, Clinical Neuropharmacology, 26(6), 297-8, Nov-Dec 2003
  • Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr (Sep-Dec 2003) Adverse Effects and Laboratory Parameters of High-dose Olanzapine Vs. Clozapine in Treatment-resistant Schizophrenia, Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists, 15 (3-4), 181-6
  • Kreyenbuhl JA, Kelly DL, Conley RR (Dec 2002) Circumstances of suicide among individuals with schizophrenia, Schizophrenia Research, 58 (2-3), 253-61
  • Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (Oct 2002) mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims, Neuropsychopharmacology, 27 (4), 499-517
  • Conley RR, Kelly DL (Apr 2002) Current status of antipsychotic treatment., Curr Drug Target Cns Neurol Disord, 1 (2), 123-8
  • Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R (Apr 2002) A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia, American Journal of Psychiatry, 159 (4), 554-60
  • McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR (Apr 2002) Novel factor-based symptom scores in treatment resistant schizophrenia: Implications for clinical trials, Neuropsychopharmacology, 26 (4), 537-45
  • Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, Roberts RC, Conley RR, Tamminga CA (Mar 2002) Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims, American Journal of Psychiatry, 159 (3), 419-29
  • Dwivedi Y, Conley RR, Roberts RC, Tamminga CA, Pandey GN (Jan 2002) [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims, American Journal of Psychiatry, 159 (1), 66-73
  • Conley RR (2002) Schizophrenia In Rakel R, Bope E (eds), Conn's Current Therapy 2002, Philadelphia, PA, W.B. Saunders Co., 1139-1144 pages (bookchapter)
  • Conley RR, Kelly DL (Dec 2001) Management of treatment resistance in schizophrenia., Biological Psychiatry, 50 (11), 898-911
  • Avila MT, Conley RR, Carpenter WT (Oct 2001) A comparison of symptom provocation procedures in psychiatry and other areas of medicine: implications for their ethical use in research, Biological Psychiatry, 50 (7), 479-86
  • Richardson C, Kelly DL, Conley RR (Aug 2001) Biperiden for excessive sweating from clozapine, The American Journal of Psychiatry, 158 (8), 1329-30
  • Conley RR, Mahmoud R (May 2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder, American Journal of Psychiatry, 158 (5), 765-74
  • Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN (May 2001) Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem of depressed suicide subjects, J Neurochem, 77 (3), 916-28
  • Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR (May 2001) Comparison of discharge rates and drug costs for patients with treated with risperidone or olanzapine, Psychiatr Serv, 52 (5), 676-8
  • Conley RR (2001) Evaluating clinical trial data: outcome measures, Journal of Clinical Psychiatry, 62 (S 9), 23-6
  • Conley RR, Kelly DL (2001) Pharmacologic Treatment of Schizophrenia, Professional Communications, Inc.
  • Conley RR (2001) Management of Treatment-Refractory Patients In Csernansky J (eds), Schizophrenia: A New Guide for Clinicians, New York. NY, Marcel Dekker, 163-182 pages (bookchapter)
  • Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (Jul 2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate, American Journal of Psychiatry, 157 (7), 1141-9
  • Carpenter WT Jr, Conley R, Kirkpatrick B, On schizophrenia and new generation drugs, Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 22(6), 660-4, Jun 2000
  • Carpenter WT Jr, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS (Jun 2000) Decisional capacity for informed consent in schizophrenia research., Arch Gen Psychiatry, 57 (6), 533-8
  • Conley RR (2000) Risperidone side effects., Journal of Clinical Psychiatry, 61 Suppl 8, 20-3
  • Conley RR, Meltzer HY (2000) Adverse events related to olanzapine., Journal of Clinical Psychiatry, 61 Suppl 8, 26-9
  • Pandey GN, Dwivedi Y, Pandey SC, Teas SS, Conley RR, Roberts RC, Tamminga CA (Dec 1999) Low phosphoinositide-specific phospholipase C activity and expression of phospholipase C beta1 protein in the prefrontal cortex of teenage suicide subjects, American Journal of Psychiatry, 156 (12), 1895-901
  • Kelly DL, Conley RR, Tamminga CA (Nov 1999) Differential olanzapine plasma concentrations by sex in a fixed-dose, Schizophrenia Research, 40 (2), 101-4
  • Kirkpatrick B, Conley R, Kakoyannis A, Reep RL, Roberts RC (Nov 1999) Interstitial cells of the white matter in the inferior parietal cortex in Schizophrenia: An Unbiased Cell-counting Study, Synapse, 34 (2), 95-102
  • Love RC, Conley RR, Kelly DL, Bartko JJ (Nov 1999) A dose-outcome analysis of risperidone., Journal of Clinical Psychiatry, 60 (11), 771-5
  • Conley RR, Tamminga CA, Kelly DL, Richardson CM (Jul 1999) Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response, Biological Psychiatry, 46 (1), 73-7
  • Conley RR, Love RC, Kelly DL, Bartko JJ (Jun 1999) Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine, Schizophrenia Research, 156 (6), 863-8
  • Carpenter WT, Conley RR (Feb 1999) Sense and nonsense: an essay on schizophrenia research ethics., Schizophrenia Research, 35 (3), 219-25; discussion 2
  • Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR (Dec 1998) Rehospitalization rates for depot antipsychotics and pharmacoeconomic, American Journal of Health-system Pharmacy, 55 (24 Suppl 4), S17-9
  • Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR, Tamminga CA (Nov 1998) Direct determination of dopamine D4 receptors in normal and schizophrenic, Molecular Psychiatry, 3 (6), 528-33
  • Conley RR, Kelly DL, Gale EA (Sep 1998) Olanzapine response in treatment-refractory schizophrenic patients with a, Schizophrenia Research, 33 (1-2), 95-101
  • Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S (Jul 1998) Olanzapine compared with chlorpromazine in treatment-resistant, American Journal of Psychiatry, 155 (7), 914-20
  • Ross DE, Thaker GK, Buchanan RW, Lahti AC, Conley R, Medoff D, Specific measures account for most of the variance in qualitative ratings of smooth pursuit eye movements in schizophrenia, Archives of General Psychiatry, 55(2), 184-6, Feb 1998
  • Kung L, Conley R, Chute DJ, Smialek J, Roberts RC (Feb 1998) Synaptic changes in the striatum of schizophrenic cases: a controlled, Synapse, 28 (2), 125-39
  • Conley RR (1998) Optimizing treatment with clozapine., Journal of Clinical Psychiatry,, 59 (S 3), 44-8
  • DeRenzo EG, Conley RR, Love R (1998) Assessment of capacity to give consent to research participation:, J Health Care Law Policy, 1 (1), 66-87
  • Lahti RA, Cochrane EV, Roberts RC, Conley RR, Tamminga CA (1998) [3H]Neurotensin receptor densities in human postmortem brain tissue, Journal of Neural Transmission, 105 (4-5), 507-16
  • Conley RR (1998) Optimizing treatment with clozapine., Journal of Clinical Psychiatry, 59 Suppl 3, 44-8
  • Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM (1998) Weight gain in adolescents treated with risperidone and conventional Weight Gain in Adolescents Treated With Risperidone and Conventional Antipsychotics Over Six Months, J Child and Adol Psychopharmacology, 8 (3), 151-9
  • Carpenter WT, Conley RR, Buchanan RW (1988) Schizophrenia In Coyle JT, Enna SJ (eds), Pharmacological Management of Neurological and Psychiatric Disorders, New York. NY, McGraw-Hill, 27-52 pages (bookchapter)
  • Conley RR, Carpenter WT Jr, Tamminga CA (Sep 1997) Time to clozapine response in a standardized trial., American Journal of Psychiatry, 154 (9), 1243-7
  • Pandey GN, Conley RR, Pandey SC, Goel S, Roberts RC, Tamminga CA, Chute D, Smialek J (Aug 1997) Benzodiazepine receptors in the post-mortem brain of suicide victims and, Psychiatry Research, 71 (3), 137-49
  • Deckelman MC, Dixon LB, Conley RR (Jul 1997) Comorbid bulimia nervosa and schizophrenia., International Journal of Eating Disorders, 22 (1), 101-5
  • Pandey GN, Dwivedi Y, Pandey SC, Conley RR, Roberts RC, Tamminga CA (Jun 1997) Protein kinase C in the postmortem brain of teenage suicide victims, Neuroscience Letters, 228 (2), 111-4
  • Conley RR, Buchanan RW (1997) Evaluation of treatment-resistant schizophrenia, Schizophrenia Bulletin, 23 (4), 663-74
  • Tamminga CA, Conley RR (1997) The application of neuroimaging techniques to drug development, Journal of Clinical Psychiatry, 58 Suppl 10, 3-6
  • Conley RR (1997) Clinical Simulations in the Management of Psychotic Disorders, Norwalk Connecticut, Medical Age Publishing
  • Conley RR (1997) Schizophrenia and Other Psychotic Disorders In Merlino J (eds), Psychiatry: An Interactive Clinical Review, New York. NY, Clinical Communications, Inc. (bookchapter)
  • Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA (Nov 1996) Clozapine conflict, The American Journal of Psychiatry, 153 (11), 1505-7
  • Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA (Aug 1996) D2-type dopamine receptors in postmortem human brain sections from normal, Neuroreport, 7 (12), 1945-8
  • Roberts RC, Conley R, Kung L, Peretti FJ, Chute DJ (Apr 1996) Reduced striatal spine size in schizophrenia: a postmortem ultrastructural, Neuroreport, 7 (6), 1214-8
  • Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA (Jun 1995) Patient response and resource management: another view of clozapine, American Journal of Psychiatry, 152 (6), 827-32
  • Conley R, Tamminga CA, Nguyen JA, Clinical action of remoxipride, Archives of General Psychiatry, 51(12), 1001, Dec 1994
  • Tamminga CA, Conley RR, Wong DF (May 1994) Human brain receptors, IV. Human in vivo receptor imaging, American Journal of Psychiatry,, 151 (5), 639
  • Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C (Oct 1993) Changes in psychopathology and dyskinesia after neuroleptic withdrawal in, Schizophrenia Research, 10 (3), 267-71
  • Dixon L, Dibietz E, Myers P, Conley R, Medoff D, Lehman AF (Aug 1993) Comparison of DSM-III-R diagnoses and a brief interview for substance use, Hospital and Community Psychiatry,, 44 (8), 748-52
  • Holcomb HH, Cascella NG, Medoff DR, Gastineau EA, Loats H, Thaker GK, Conley RR, Dannals RF, Wagner HN Jr, Tamminga CA (Sep-Oct 1993) PET-FDG test-retest reliability during a visual discrimination task in, Journal of Computer Assisted Tomography, 17 (5), 704-9
  • Tamminga CA, Shirakawa O, Conley RR (1993) Nontarget Actions of Neuroleptics In Brunello N, Mendlewicz J, Racagni G (eds), New Generations of Antipsychotic Drugs: Novel Mechanisms of Action Int. Acad. Biomed. Drug Res., Volume 4 Edition, Basel, Karger, 67-76 pages (bookchapter)
  • Baker RW, Conley RR (Sep 1991) Seizures during clozapine therapy, The American Journal of Psychiatry, 148 (9), 1265-6
  • Davies MA, Conley RR, Schulz SC, Bell-Delaney J (Jun 1991) One-year follow-up of 24 patients in a clinical trial of clozapine, Hospital and Community Psychiatry, 42 (6), 628-9
  • Carpenter WT, Conley RR (1991) Therapeutic Approaches to Negative Symptoms In Greden JF, Tandon R (eds), Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications, Series Number 28 Edition, Washington DC and London, American Psychiatric Press, 205-214 pages (bookchapter)
  • Conley RR, Baker RW (Aug 1990) Family response to improvement by a relative with schizophrenia, Hospital and Community Psychiatry, 41 (8), 898-901
  • Schulz SC, Kahn EM, Baker RW, Conley RR (1990) Lithium and Carbamazepine Augmentation in Treatment Refractory Schizophrenia In Angrist B (eds), The Neuroleptic-Nonresponsive Patient:Characterization and Treatment. Progress in Psychiatry, Series Number 27 Edition, Washington DC and London, American Psychiatric Press, 111-136 pages (bookchapter)
  • Schulz SC, Conley RR, Kahn EM (1989) Nonresponders to neuroleptics: a distinct subtype In Tamminga CA (eds), Schizophrenia: Scientific Progress, New York. NY, Oxford University Press, 333-340 pages (bookchapter)
  • Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA (1988) Clozapine efficacy in schizophrenic nonresponders, Psychopharmacology Bulletin, 24 (2), 269-74
  • Cohen RL, Conley RR, Henderson PB: (1987) Moonlighting: A Realistic Approach In Dulcan MK (eds), Basic Handbook of Training in Child and Adolescent Psychiatry, Springfield, Illinois, Charles C. Thomas, 308-320 pages (bookchapter)
  • Conley RR, Pigiet V (Aug 1978) In vivo distribution of phosphothioredoxin and thioredoxin in Escherichia, Journal of Biological Chemistry,, 253 (16), 5568-72
  • Pigiet V, Conley RR (Mar 1978) Isolation and characterization of phosphothioredoxin from Excherichia, Journal of Biological Chemistry,, 253 (6), 1910-20
  • Pigiet VP, Conley RR (Sep 1977) Purification of thioredoxin, thioredoxin reductase, and glutathione, Journal of Biological Chemistry, 252 (18), 6367-72

Profile Details

Last Updated: 3/24/2006

COS Expertise ID #532858
Reference this profile directly: http://myprofile.cos.com/rconley